Seres Therapeutics FY GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $126.33M Beat $126.07M Estimate
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics (NASDAQ:MCRB) reported FY GAAP EPS of $(0.89), surpassing the $(0.96) estimate, and sales of $126.33M, exceeding the $126.07M estimate. This represents a significant improvement over the previous year, with a 61.47% decrease in losses per share and a 1.67K% increase in sales.
March 05, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics reported a significant earnings beat and a massive increase in sales, indicating strong financial performance.
The positive earnings report from Seres Therapeutics, with a substantial beat on both EPS and sales estimates, indicates a strong financial turnaround and operational efficiency. This performance, especially the significant year-over-year sales increase, is likely to instill investor confidence and could lead to a short-term positive impact on MCRB's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100